Physician profile
Britto Chinnappan
NPI 1750477709
$4,421.56
in general payments reported to CMS, 2019-2025
23 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $441 · 2021: $299 · 2022: $655 · 2023: $605 · 2024: $783 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $832.37 | 2019-2025 | Jardiance |
| Amgen INC. | $621.32 | 2019-2025 | Repatha, Evenity, Repatha |
| Novo Nordisk INC | $505.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $448.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $300.97 | 2019-2025 | |
| Lilly USA, LLC | $274.61 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $268.90 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $223.91 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $214.53 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $125.35 | 2019-2024 | Capvaxive |
| Alnylam Pharmaceuticals INC. | $96.99 | 2022 | |
| Abbott Laboratories | $82.72 | 2022-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $74.00 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $53.14 | 2025 | |
| Sanofi-Aventis U.S. LLC | $48.25 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $47.46 | 2019-2023 | Livalo |
| Paratek Pharmaceuticals, INC. | $33.99 | 2022-2023 | Nuzyra |
| Azurity Pharmaceuticals, INC. | $30.24 | 2025 | Edarbi |
| Amarin Pharma, INC. | $29.92 | 2019 | |
| Inspire Medical Systems, INC. | $28.52 | 2025 | Inspire |
| Allergan, INC. | $26.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.59 | 2019 | |
| Corcept Therapeutics | $26.43 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britto Chinnappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.